Hepatobiliary cancer + +... + +...

Toripalimab plus bevacizumab versus sorafenib as first-line treatment for advanced hepatocellular carcinoma (HEPATORCH): a randomised, open-label, phase 3 trial https://www.thelancet.com/journals/langas/article/PIIS2468-1253(25)00059-7/abstract?utm_campaign=infocusalerts-oncology&utm_medium=email&dgcid=hubspot_email_infocusalerts-oncology_feature&_hsenc=p2ANqtz-9o7oG5N_iM-hjusMsD8kZlreFlslDZ5vyaZDOm-BlDXu4ZrAUzapMWWSkjTuAWWtql2kUyKL8aNroOvUEpqcs-ntnjOQ&_hsmi=376202211&utm_content=375562311&utm_source=hs_email Hepatobiliary cancer https://www.thelancet.com/collections/hepatobiliary-cancer?dgcid=hubspot_email_infocusalerts-oncology_feature&parent=001611&startPage=&ContentItemType=fla&utm_campaign=infocusalerts-oncology&utm_medium=email&_hsenc=p2ANqtz-8NfyRLS0hTCc5uy-Pcr-79imP5RMPacwPGI32O3QLVVgwvEVaZOC9G_zTI1cFexiy8lAFWyIfIOM1JMBhjXQ5Henub_g&_hsmi=376202211&utm_content=375562311&utm_source=hs_email Risk of cardiovascular disease among cancer survivors: systematic review and meta-analysis https://www.thelancet.com/journals/eclinm/article/PIIS2589-5370(25)00206-8/fulltext?dgcid=hubspot_email_infocusalerts-oncology_feature&utm_campaign=infocusalerts-oncology&utm_medium=email&_hsenc=p2ANqtz-8fjE55gW_F3znjSE16ZkaIflzsJ44NLqlJCI0rZQ_WejiSK7zXerI17oZmPEBeRONGejk7Q6KSiFl4P159VK2sFt2a4A&_hsmi=376202211&utm_content=375562311&utm_source=hs_email Viewpoint The potential role of mifepristone in breast cancer prevention: beyond medical abortion https://www.thelancet.com/collections/oncology?parent=